Evolus (EOLS) Competitors $9.15 +0.23 (+2.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$9.10 -0.05 (-0.55%) As of 08/1/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. IBRX, BHC, AGIO, CNTA, BEAM, TWST, KNSA, IRON, GLPG, and CGONShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include ImmunityBio (IBRX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Kiniksa Pharmaceuticals International (KNSA), Disc Medicine (IRON), Galapagos (GLPG), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Its Competitors ImmunityBio Bausch Health Cos Agios Pharmaceuticals Centessa Pharmaceuticals Beam Therapeutics Twist Bioscience Kiniksa Pharmaceuticals International Disc Medicine Galapagos CG Oncology Evolus (NASDAQ:EOLS) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation. Do analysts recommend EOLS or IBRX? Evolus currently has a consensus target price of $23.75, suggesting a potential upside of 159.56%. ImmunityBio has a consensus target price of $12.25, suggesting a potential upside of 416.88%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Evolus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has stronger valuation & earnings, EOLS or IBRX? Evolus has higher revenue and earnings than ImmunityBio. Evolus is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M2.22-$50.42M-$0.89-10.28ImmunityBio$14.74M141.91-$413.56M-$0.58-4.09 Is EOLS or IBRX more profitable? Evolus has a net margin of -20.40% compared to ImmunityBio's net margin of -1,310.30%. ImmunityBio's return on equity of 0.00% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-20.40% -759.04% -20.14% ImmunityBio -1,310.30%N/A -121.88% Which has more risk and volatility, EOLS or IBRX? Evolus has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Do institutionals and insiders hold more shares of EOLS or IBRX? 90.7% of Evolus shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 5.9% of Evolus shares are held by insiders. Comparatively, 76.8% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to EOLS or IBRX? In the previous week, ImmunityBio had 1 more articles in the media than Evolus. MarketBeat recorded 4 mentions for ImmunityBio and 3 mentions for Evolus. ImmunityBio's average media sentiment score of 0.64 beat Evolus' score of -0.05 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryImmunityBio beats Evolus on 10 of the 17 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$575.12M$10.40B$5.48B$9.54BDividend YieldN/A1.99%4.73%4.09%P/E Ratio-10.2818.4228.8623.83Price / Sales2.2229.01371.4566.14Price / CashN/A22.3135.4557.96Price / Book101.673.478.265.54Net Income-$50.42M$234.77M$3.25B$259.28M7 Day Performance-3.99%-4.82%-3.75%-4.67%1 Month Performance-0.65%1.80%4.27%4.37%1 Year Performance-33.98%-12.51%25.85%17.91% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus3.5291 of 5 stars$9.15+2.6%$23.75+159.6%-34.8%$575.12M$266.27M-10.28170News CoverageUpcoming EarningsIBRXImmunityBio2.2314 of 5 stars$2.68-2.5%$12.25+357.1%-50.5%$2.37B$14.74M-4.62590News CoverageGap DownBHCBausch Health Cos4.6455 of 5 stars$6.34+0.4%$7.30+15.2%-6.4%$2.34B$9.63B-57.6020,700News CoverageEarnings ReportAnalyst UpgradeAGIOAgios Pharmaceuticals4.0161 of 5 stars$39.92-0.2%$58.60+46.8%-21.3%$2.31B$37.04M3.55390News CoverageEarnings ReportCNTACentessa Pharmaceuticals3.2078 of 5 stars$16.06+2.4%$28.10+75.0%+63.4%$2.14B$6.85M-8.87200News CoverageAnalyst ForecastInsider TradeBEAMBeam Therapeutics2.6098 of 5 stars$21.03+1.3%$48.75+131.8%-37.9%$2.11B$63.52M-4.56510Upcoming EarningsInsider TradeGap DownTWSTTwist Bioscience3.5566 of 5 stars$34.77-1.1%$50.40+45.0%-36.5%$2.08B$312.97M-10.70990News CoverageUpcoming EarningsShort Interest ↑Gap DownKNSAKiniksa Pharmaceuticals International3.1499 of 5 stars$28.42-2.1%$39.33+38.4%+24.1%$2.07B$423.24M-113.68220News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionIRONDisc Medicine3.5418 of 5 stars$59.38+2.8%$95.73+61.2%+36.3%$2.06BN/A-15.1530Positive NewsUpcoming EarningsInsider TradeGLPGGalapagos0.3701 of 5 stars$32.14+3.2%$25.33-21.2%+21.6%$2.05B$288.19M0.001,310CGONCG Oncology1.9211 of 5 stars$26.90+0.6%$55.30+105.6%-22.3%$2.05B$1.14M-17.8161News CoverageGap Down Related Companies and Tools Related Companies ImmunityBio Competitors Bausch Health Cos Competitors Agios Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Beam Therapeutics Competitors Twist Bioscience Competitors Kiniksa Pharmaceuticals International Competitors Disc Medicine Competitors Galapagos Competitors CG Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
